• Novavax, Inc. recently reported its second-quarter 2026 results, with revenue of US$56.7 million versus US$239.24 million a year earlier and a net loss of US$53.39 million compared with net income of US$106.51 million.
• Over the first half of 2026, revenue dropped to US$196.21 million from US$905.90 million, while results swung from net income of US$625.15 million to a loss of US$62.88 million, sharply reversing the company’s prior profitability.
• We’ll now examine how this sharp year-over-year deterioration in revenue and earnings reshapes Novavax’s investment narrative built around partnerships and royalties.

Outshine the giants: these 17 early-stage AI stocks could fund your retirement.

Novavax Investment Narrative Recap

To own Novavax today, you need to believe its partnerships and Matrix M royalties can eventually support a steadier, less COVID dependent business. The sharp Q2 2026 revenue and profit reversal puts fresh focus on the most important near term catalyst: execution under the Sanofi, Pfizer, and Takeda deals, while amplifying the key risk around earnings volatility and liquidity if milestone timing and partner sales remain uneven.

The Q2 setback now sits alongside the January 2026 Pfizer Matrix M licensing agreement, which brought a US$30 million upfront payment and the prospect of future milestones and royalties. This deal is highly relevant here because it highlights how dependent Novavax has become on third party adoption of its adjuvant to offset weak product revenue, reinforcing both the upside potential of successful licensing and the downside if partner programs stall or underperform.

Yet beneath these headline numbers, one issue in particular could catch investors off guard if partner driven royalties fall short and...

Novavax’s narrative projects $348.5 million revenue and $55.9 million earnings by 2028.

Uncover how Novavax's forecasts yield a $13.78 fair value, a 57% upside to its current price.

Exploring Other Perspectives

Compared with the consensus view, the lowest analysts were already assuming revenue could fall about 25% a year and still only reach roughly US$250 million by 2029, so after this weak Q2 print you may find their more pessimistic take on Matrix M licensing and long term earnings worth exploring alongside the baseline narrative.

Explore 4 other fair value estimates on Novavax - why the stock might be worth over 6x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Novavax research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Novavax research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Novavax's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 52 companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.